Already have an account?


Login with an existing Projects In Knowledge account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.



New and Noteworthy


  • Pulmonology — Chapter 4.2: Approved and Emerging Treatments for Cystic Fibrosis: Underlying Cause – @Point of Care Chapter
  • The first agent targeting the underlying cause of cystic fibrosis (CF) was approved in 2011, more than 20 years after the underlying genetic defect was first identified. Advances in screening technologies have led to the identification of even more compounds with the potential to address the underlying cause. ... more >>
    S. McColley, MD
  • Pulmonology — Chapter 4.3: Managing the Complexity of Drug Therapy in Individuals with Cystic Fibrosis – @Point of Care Chapter
  • In recent years, tremendous advances have been made in the management of cystic fibrosis (CF). New medications are improving clinical outcomes and increasing survival. However, with these advancements, CF treatment regimens have become more complicated and time-consuming, and new challenges are emerging ... more >>
    S. McColley, MD
  • Pulmonology — Chapter 2.2: CFTR Mutations in the Pathophysiology of Cystic Fibrosis – @Point of Care Chapter
  • Understanding and interpreting the molecular genetic results for cystic fibrosis (CF) genotyping presents challenges for the practicing clinician in the current era of genomic sequencing. Although it has been more than 25 years since the discovery of the causal gene, CF research has only recently made huge ... more >>
    S. McColley, MD
  • Pulmonology — Cystic Fibrosis @Point of Care (powered by IBM Watson) – @Point of Care
  • Major advancements, including newborn screening, new treatments targeting the underlying cause of disease, and quality improvement initiatives, have transformed the continuum of care and survival outcomes for individuals with cystic fibrosis. The Cystic Fibrosis @Point of Care Edition provides a comprehensive ... more >>
    S. McColley, MD
  • Pulmonology — Chapter 3.1: Newborn Screening, Diagnosis, & Prognosis of Cystic Fibrosis – @Point of Care Chapter
  • This subchapter reviews newborn screening and early diagnosis of cystic fibrosis (CF). In addition, diagnostic tools and categories, symptoms, and outcomes of early screening are discussed. Throughout the subchapter, you will find supportive multimedia hyperlinks that provide access to videos, journal ... more >>
    S. McColley, MD
  • Pulmonology — Chapter 4.1: Current & Emerging Treatments for Cystic Fibrosis: Symptom and Nutritional Management – @Point of Care Chapter
  • Cystic fibrosis (CF) presents challenges for the practicing clinician. It is an inherited and lifelong disease for which there is no cure. Furthermore, the treatment and management of CF is complex and burdensome, often leading to suboptimal health and outcomes in many individuals. Join Peter Mogayzel, MD, ... more >>
    S. McColley, MD
  • Pulmonology — Chapter 1.1: Epidemiology of Cystic Fibrosis – @Point of Care Chapter
  • This subchapter reviews the history of cystic fibrosis (CF) as well as the incidence and prevalence of the disease. In addition, the impact of newborn screening, microbial eradication, and pulmonary exacerbations on the prevalence, morbidity, and mortality of CF are discussed. Throughout this subchapter you ... more >>
    S. McColley, MD
  • Pulmonology — Chapter 2.1: Etiology and Pathophysiology of Cystic Fibrosis – @Point of Care Chapter
  • Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Expression of CFTR occurs in the epithelia of many organs, including the lungs, pancreas, liver, intestine, reproductive tract, and sweat glands. Loss of function ... more >>
    S. McColley, MD
  • Pulmonology — Chapter 5.3: Preventing and Managing Lung Complications in Individuals with Cystic Fibrosis – @Point of Care Chapter
  • Cystic fibrosis (CF), an inherited and lifelong disease for which there is no cure, presents challenges for clinicians. Because the treatment and management of CF is complex and burdensome, outcomes are often suboptimal in many individuals. Join Dr. Peter Mogayzel, Jr as he reviews current best practices and ... more >>
    S. McColley, MD
  • Pulmonology — Chapter 5.2: Managing the Transition from Pediatric to Adolescent/Adult Care – @Point of Care Chapter
  • Cystic fibrosis (CF) presents challenges for the practicing clinician. It is an inherited and lifelong disease for which there is no cure. Furthermore, the treatment and management of CF is complex—involving multiple treatments as well as behavioral and psychosocial issues—and burdensome, which can complicate ... more >>
    S. McColley, MD
  • Clinical Context: Diagnosis & Treatment of PBC and NASH

  • Clinical Context: Diagnosis and Treatment of PBC and NASH is designed to provide up-to-date information on patient identification, symptoms, risk factors, and current and emerging treatments and best practices in the management of PBC and NASH.

    The curriculum includes:
    • 4 case studies at the point of
    ...
    more >>
    Z. Younossi, MD, MPH, FACG
  • Multiple Sclerosis: The Advanced Curriculum VII
  • Ongoing research in the field of multiple sclerosis (MS) has generated new insights into the pathophysiology, diagnosis, treatment, and management of this challenging disease. A wide array of new MRI technologies, new treatment strategies, and a better understanding of the need for early diagnosis and ... more >>
    F. Lublin, MD
    A. Miller, MD
  • Curriculum In Context: Multiple Myeloma

  • Curriculum In Context: Multiple Myeloma is designed to provide up-to-date information on patient identification, symptoms, risk factors, and current and emerging treatments and best practices in the management of multiple myeloma. The curriculum includes six case studies at the point of care, a webcast, ...
    more >>
    N. Raje, MD
  • Curriculum In Context: Hepatitis C Virus

  • Curriculum In Context: Hepatitis C Virus (HCV) is designed to provide up-to-date information on patient identification, symptoms, risk factors, and current and emerging treatments and best practices in the management of HCV. The curriculum includes six case studies at the point of care and MedPage Today ...
    more >>
    P. Kwo, MD
    Z. Younossi, MD, MPH, FACG
  • Curriculum In Context: Inflammatory Bowel Disease

  • Curriculum In Context: Inflammatory Bowel Disease (IBD) is designed to provide up-to-date information on patient identification, symptoms, risk factors, and current and emerging treatments and best practices in the management of IBD. The curriculum includes six case studies at the point of care and ...
    more >>
    D. Rubin, MD
    L. Weinstock, MD, FACG
  • Multiple Sclerosis: The Advanced Curriculum VI
  • Ongoing research in the field of multiple sclerosis (MS) has generated new insights into the pathophysiology, diagnosis, treatment, and management of this challenging disease. A wide array of new MRI technologies, new treatment strategies, and a better understanding of the need for early diagnosis and ... more >>
    F. Lublin, MD
    A. Miller, MD
  • Curriculum In Context: Multiple Myeloma

  • Curriculum In Context: Multiple Myeloma is designed to provide up-to-date information on patient identification, symptoms, risk factors, and current and emerging treatments and best practices in the management of multiple myeloma. The curriculum includes six case studies at the point of care and MedPage ...
    more >>
    K. Anderson, MD
  • Idiopathic Pulmonary Fibrosis: Case Studies
  • Idiopathic Pulmonary Fibrosis—Case Studies is a series of compelling CME/CE-accredited case studies that deliver the latest scientific data about the management of idiopathic pulmonary fibrosis, framed around real-world patient scenarios commonly seen in daily practice. The case simulations add a level of ... more >>
    M. Padilla, MD
  • A Curriculum for the Management of T2DM Patients with SGLT-2 Inhibitors
  • The unprecedented increase in recently improved and emerging antidiabetic agents seen over the last few years has dramatically expanded the ability of clinicians to treat patients with type 2 diabetes. Among the newest of these agents are the sodium glucose cotransporter 2 (SGLT-2) inhibitors, a class of ... more >>
    V. Fonseca, MD, FRCP
  • Case-Based Practice Improvement Video Vignette Collection: Rheumatoid Arthritis Edition
  • Through a collection of six patient video case vignettes, this point-of-care clinical companion provides rheumatologists and other clinicians with valuable instruction on the use of disease-modifying antirheumatic drugs (DMARDs), and current and emerging biologic agents as initial treatment for patients with ... more >>
    D. Furst, MD, MSPH
  • MedImage Cases-Neurology: Multiple Sclerosis
  • The MS MedImage Cases® library discusses the MRI as a tool to guide practical therapeutic approaches and measure disease activity, progression, and response to therapy. New collaboration tools: Share Your Knowledge® comment on a particular aspect of a presented case. Share Your Case® €”submit a challenging ... more >>
    D. Pelletier, MD
  • Cystic Fibrosis @Point of Care (powered by IBM Watson)
  • Major advancements, including newborn screening, new treatments targeting the underlying cause of disease, and quality improvement initiatives, have transformed the continuum of care and survival outcomes for individuals with cystic fibrosis. The Cystic Fibrosis @Point of Care Edition provides a comprehensive ... more >>
    S. McColley, MD
  • Asthma @Point of Care
  • Asthma @Point of Care™ platform provides a comprehensive knowledge base of current and emerging diagnostic and management strategies based on the most up-to-date scientific data and clinical trial results, guidance, and insights from top clinician specialists all delivered in ways to efficiently and ... more >>
    M. Wechsler, MD, MMSc
  • Update - Making Sense of New and Emerging Treatment Options for COPD
  • Chronic obstructive pulmonary disease (COPD) is highly prevalent in the United States. About 13 million people have a diagnosis of COPD, yet the disease remains underdiagnosed, with an estimated 21 million individuals affected. Cigarette smoking is the primary cause and, while smoking rates have dropped, they ... more >>
    B. Make, MD
  • Rheumatoid Arthritis @Point of Care
  • Early diagnosis, prompt intervention, and maintenance of tight disease control are now known to be key in preventing or slowing progression of rheumatoid arthritis (RA). Many patients do not achieve or sustain remission with older disease-modifying agents alone. Biologic therapies for RA have helped many ... more >>
    P. Mease, MD
  • Parkinson's Disease @Point of Care
  • From 2005 to 2030, the number of patients with Parkinson’s disease is expected to double. Caroline M. Tanner, MD, PhD provides an overview of the epidemiology of Parkinson’s disease and its associated morbidity in this subchapter of the Parkinson’s Disease @POC program.
    R. Hauser, MD, MBA
  • Myelodysplastic Syndromes and Acute Myeloid Leukemia @Point of Care
  • The Myelodysplastic Syndromes and Acute Myeloid Leukemia @Point of Care is always updated and always current. Point of care accessibility allows clinicians to answer practice-based questions by accessing a robust and easily searchable knowledge base, this interactive point-of-care resource tool offers expert- ... more >>
    J. Radich, MD, MS
  • Advances in Immuno-Oncology
  • Immuno-Oncology @Point of Care, featuring Jeffrey S. Weber, MD, PhD as Editor-in-Chief, is a clinical support platform that provides comprehensive information on immuno-oncology and the role of immune-based medicines in treating cancer, made up of a progressive series of chapters and other learning tools. It ... more >>
    J. Weber, MD, PhD
  • Non-Small Cell Lung Cancer @Point of Care
  • Advances in our understanding of non-small-cell lung cancer (NSCLC) are leading to new strategies for diagnosis, staging, and treatment. This point-of-care clinical resource can help you stay informed about disease pathogenesis, molecular targets, and current and emerging management strategies based on the ... more >>
    M. Socinski, MD
  • Hypoparathyroidism @Point of Care
  • Rare disorders, such as hypoparathyroidism, present a challenge for clinicians to keep abreast of new developments and changes in best practices. The Hypoparathyroidism @Point of Care Edition provides a comprehensive examination of the latest evidence-based data for optimizing current patient identification, ... more >>
    J. Bilezikian, MD
  • Primary Biliary Cirrhosis — Practice-Changing Trends in PBC and NASH – Satellite Symposium
  • Registration for the live symposium has now ended. If you would like to attend this live event, please arrive at the Marriott Marquis, Independence Ballroom, Salons D&E, by 6:00pm for onsite registration.

    This program is not affiliated with Digestive Disease Week®.

    Primary biliary cirrhosis (PBC) and ...
    more >>
    A. Sanyal, MD
  • Diabetes — Advances in Insulin Therapies for the Treatment of T1DM and T2DM – Webcast
  • Determining insulin treatment for patients with type 1 and type 2 diabetes presents a variety of challenges for the physician. In addition to reluctance on the part of patients, and sometimes physicians, to begin insulin, new therapeutic classes and agents – both insulin and non-insulin – have recently ... more >>
    V. Fonseca, MD, FRCP
  • Primary Biliary Cirrhosis — PBC and NASH: Progress on the Horizon – Webcast
  • Chronic liver diseases, such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH), are leading causes of morbidity and mortality in the United States. PBC and NASH differ with respect to their epidemiology, presentation, management options, and response to treatment. The burden of these ... more >>
    A. Sanyal, MD
  • Multiple Myeloma — Focus on the Role of Proteasome Inhibitors in the Management of Multiple Myeloma – Webcast
  • Clinicians need to know how to incorporate proteasome inhibitors into treatment plans for patients with multiple myeloma, whether they are newly diagnosed or are experiencing relapsed/refractory disease. Join our co-faculty Sagar Lonial, MD, and Kenneth C. Anderson, MD, for this webcast, Focus on the Role of ... more >>
    S. Lonial, MD
  • Pulmonology — Making Sense of New and Emerging Treatment Options for COPD – Webcast
  • Recent advances have led to important changes in the paradigm for the treatment of COPD. Join Dr. Barry Make and Dr. James Donohue as they discuss the current emphasis on personalized treatment based on expanded factors in patient assessment, together with the development of new and emerging treatment options ... more >>
    B. Make, MD
  • Hepatitis C — Hepatitis C Treatment Goes Viral: Let's Talk About Oral Therapies – Webcast
  • This compelling webcast features expert-guided presentations on the current state of oral therapies for chronic hepatitis C virus (HCV) infection. Learn the implications of clinical trial results, and how the latest advances are affecting today's real-world clinical practice.
    I. Jacobson, MD
  • Primary Biliary Cirrhosis — Changing Dynamics in the Science and Clinical Management of Primary Biliary Cirrhosis: What they Mean for Us, What They Mean for Our Patients – Webcast
  • There are several types of chronic liver disease, including primary biliary cirrhosis (PBC), and there remain several challenges in the management of this disease. Join Dr. David Jones, Program Chair, and Dr. Ulrich Beuers, Distinguished Faculty, as they offer insight into recent developments in the ... more >>
    D. Jones, MD, PhD
  • Multiple Sclerosis — Improving the Management of Walking Impairment and Foot Drop in MS – Webcast
  • Almost two-thirds of MS patients report significant difficulty in walking. Yet, approximately 40% of patients with MS rarely or never discuss this problem with their physicians. As a result of this gap in communication, many MS patients do not experience the benefits of available pharmacologic and ... more >>
    A. Goodman, MD
  • Primary Biliary Cirrhosis — Novel Therapeutic Targets in PBC, PSC, and NASH: Translating Knowledge into Tomorrow's Practice – Webcast
  • There are several types of chronic liver disease, including primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH), and each disease state differs with respect to its epidemiology, presentation, management options, and response to treatment. Management ... more >>
    H. Bodenheimer Jr, MD
  • Tumor Immunology — Highlights from ASCO 2013: Novel Therapies for Advanced Melanoma – Podcast Series
  • With more effective therapies for advanced melanoma badly needed, the advent of anti-CTLA-4 and anti-PD-1 antibodies, along with other emerging agents, has been an exciting development. Join four experts in the field as they present highlights from ASCO 2013 in this breaking area.
    J. Weber, MD, PhD
  • Multiple Sclerosis — Case Study #4: Treatment Decisions at Diagnosis and Breakthrough for Male Patients with Relapsing-Remitting MS Who Desire to Have Children – Case Study
  • This case study highlights two issues that clinicians who care for patients with multiple sclerosis (MS) routinely address: breakthrough disease and reproductive concerns. Join Anne H. Cross, MD, as she models making treatment decisions for a male MS patient, a 40-year-old father who desires to have more ... more >>
    A. Cross, MD
  • Multiple Myeloma — Multiple Myeloma Case Study: Refractory MM Patient: Efficacy with Immunomodulatory Therapy – Case Study
  • Patients with multiple myeloma (MM) who are refractory after two prior regimens have a poor prognosis. However, newer treatments provide effective options for these challenging patients. In this case study, Sara Bringhen, MD, PhD, discusses the importance of choice of treatment for an elderly patient with ... more >>
    S. Bringhen, MD, PhD
  • Multiple Myeloma — High-Risk Relapsing MM Patient: Efficacy of a Proteasome Inhibitor – Case Study
  • Patients who are at high risk for progression and are in good clinical condition should be considered for induction therapy with a novel agent and autologous stem cell transplantation . In this case, Dr. Bringhen discusses induction therapy and presents evidence to support the use of proteasome inhibitor ... more >>
    S. Bringhen, MD, PhD
  • Multiple Myeloma — Relapsed/Refractory MM in a Higher-Risk Patient: Efficacy with Proteasome Inhibitor Therapy – Case Study
  • For patients with multiple myeloma who have relapsed or are refractory, adverse effects from prior therapies further complicate the choice of continued treatment. In this case presentation, Dr. Vij discusses options offered by a new proteasome inhibitor for the therapy of relapsed patients who have ... more >>
    R. Vij, MD
  • Multiple Myeloma — Relapsing MM in a High-Risk Patient: Efficacy with Proteasome Inhibitor Retreatment – Case Study
  • Bortezomib and lenalidomide, either together or with other drugs, have become mainstays of multiple myeloma therapy. However, until recently, patients who relapse on these treatments have had limited alternatives. In this case presentation, Dr. Ravi Vij discusses options offered by a new proteasome inhibitor ... more >>
    R. Vij, MD
  • Multiple Sclerosis — Case Study #3: Management of Patients with Relapsing-Remitting MS and Worsening Disease on Interferon-Beta Therapy – Case Study
  • A patient with relapsing-remitting multiple sclerosis presenting with worsening disease while on a first disease-modifying therapy is not an uncommon scenario for the practicing neurologist. This scenario, however, raises complex and critical questions. How to evaluate relapse? How to choose a personalized ... more >>
    S. Krieger, MD
  • Multiple Sclerosis — Case Study #2: Management of Multiple Sclerosis Patients Who Are Positive for the Anti-JC Virus Antibody – Case Study
  • Navigating the multiple sclerosis disease-modifying therapy options for patients who need to switch therapy due to the development of more active disease, particularly for patients who are positive for anti-JC virus antibody, is a common challenge for clinicians. Join Patricia K. Coyle, MD, for this case ... more >>
    P. Coyle, MD
  • Multiple Myeloma — Refractory MM in a High-Risk Patient: Efficacy with Proteasome Inhibitor Therapy – Case Study
  • Treatment of patients with relapsed multiple myeloma presents several challenges. In addition to determining the regimen most likely to achieve response in an individual patient, clinicians must consider the adverse effects associated with each therapy. In the past few years, the development of new ... more >>
    C. Hofmeister, MD
    D. Sborov, MD
  • Multiple Myeloma — High-Risk Relapsing MM: Efficacy with Retreatment with Immunomodulatory Therapy – Case Study
  • Patients with CRAB-negative myeloma, previously categorized as ultra-high-risk smoldering myeloma, are at high risk for early disease progression and should be considered for early intervention. In this case, Drs. Douglas W. Sborov and Craig C. Hofmeister discuss the diagnostic criteria and optimal treatment ... more >>
    C. Hofmeister, MD
    D. Sborov, MD
  • Multiple Sclerosis — Case Study #1: Diagnosis of Multiple Sclerosis and Selection of Initial Disease-Modifying Therapy in a Prototypical MS Patient – Case Study
  • The prototypical patient with multiple sclerosis (MS) is a young woman with a relapsing-remitting disease course. In this case study, Patricia K. Coyle, MD, follows the case of a 28-year-old newly married woman who presents with visual symptoms and a past history of Lhermitte’s phenomenon. Join Dr. Coyle as ... more >>
    P. Coyle, MD